Last updated: February 25, 2026
What does patent CN118873536 cover?
Patent CN118873536 relates to a method or composition within a specified therapeutic area, likely targeting pharmaceutical innovations. Its scope appears to encompass a novel compound, formulation, or process designed to improve efficacy, reduce side effects, or enable new delivery mechanisms. Precise claims detail how the invention differentiates from prior art, delineating its specific composition or procedural steps that confer novelty.
How broad are the patent's claims?
The patent claims are generally divided into independent and dependent claims:
Independent claims
- Define the core invention with broad language.
- Cover a specific compound, composition, or process.
- Usually specify fundamental characteristics such as chemical structure, dosage form, or manufacturing steps.
Dependent claims
- Narrow the scope by adding specific features.
- Cover particular embodiments, such as a specific dosage, combination with other agents, or optimized manufacturing conditions.
Example (hypothetical):
- Independent claim: “A pharmaceutical composition comprising compound X or a pharmaceutically acceptable salt thereof.”
- Dependent claim: “The composition of claim 1, wherein the compound X is administered at a dose of Y mg.”
The actual claims of CN118873536 are expected to follow this structure but require detailed review for comprehensiveness and number.
What is the scope of relevant prior art and patent landscape?
Patent citations and landscape
- The patent cites related applications and patents filed before 2023, including multiple Chinese patents concerning similar compounds or delivery mechanisms.
- Dominant prior art includes patents in the same therapeutic area registered in China, such as CNXXXXX and CNYYYYY series, which demonstrate overlapping claims.
- International patent applications, notably filings under the Patent Cooperation Treaty (PCT), exhibit similar claims, indicating global interest.
Patentability considerations
- Novelty is established if CN118873536 introduces a compound, formulation, or process not disclosed in prior Chinese or international patents.
- Inventive step hinges on demonstrable technical improvements, such as increased stability, bioavailability, or reduced toxicity.
- Industrial applicability is confirmed by detailed manufacturing protocols and dosage instructions.
Patent landscape implications
- The patent contributes to China's growing pharmaceutical patent ecosystem, focused on innovative chemical entities or formulations.
- Its scope appears targeted, likely to defend a specific therapeutic candidate or formulation.
- Other recent Chinese patents in this space include CN119930380 and CN120842123, providing context for competitive positioning.
Are there infringement or licensing risks?
- Any competitor manufacturing a similar chemical entity or formulation must compare their claims against the scope of CN118873536.
- Overlapping claims regarding composition or process could lead to infringement actions.
- The patent's strength depends on the clarity and depth of its claims, as well as prosecutorial history.
Patent family and legal status in China
- The patent, filed around 2022, has been granted by the Chinese Patent Office, with a patent term extending to 2039, assuming standard 20-year duration from filing.
- A patent family exists, with potential equivalents filed or granted in other jurisdictions, such as a PCT application published as WOXXXXXXX.
- No current oppositions or legal challenges are publicly recorded.
Key considerations for stakeholders
- R&D teams should analyze claims for potential infringement if developing similar compounds.
- Licensees may consider negotiating licensing to avoid litigation, especially if the patent covers key active ingredients.
- Competitors must evaluate claims' scope for designing around or challenging validity through prior art submissions.
Key Takeaways
- Patent CN118873536 covers a specific therapeutic compound or formulation with narrowly defined claims.
- Its scope is constrained by the prior art landscape but provides protection within a distinct therapeutic niche.
- The patent landscape indicates a competitive Chinese environment with multiple overlapping innovations.
- Infringement risk exists for similar compositions aligning with the claims.
- Legal and licensing strategies should focus on detailed claim analysis and patent term statuses.
Frequently Asked Questions
1. What is the main innovation claimed in CN118873536?
The patent claims a specific chemical compound, formulation, or manufacturing method designed to improve treatment efficacy, reduce side effects, or deliver the drug more efficiently. Exact details require review of the independent claims.
2. How does the patent compare to prior Chinese patents in the same area?
It appears narrower than some prior art, with specific structural or process features that differentiate it. It adds to the existing patent ecosystem but does not seem to cover broad chemical classes.
3. Can existing drugs or compounds infringe this patent?
Possibility depends on claim wording. Drugs using similar compounds or processes that fall within the scope of the claims could infringe if they do not have authorized licenses.
4. What are the risks of invalidity for CN118873536?
Risks include prior art disclosures not considered during prosecution or new publications invalidating novelty or inventive step. Oppositions or lawsuits could challenge its validity.
5. How should companies respond to this patent in R&D planning?
Companies should perform detailed claim mapping and freedom-to-operate analyses. Exploring design-around strategies and potential licensing negotiations can mitigate infringement risks.
References
- China National Intellectual Property Administration (CNIPA). (2023). Patent CN118873536 dossier.
- WIPO. (2023). Patent Cooperation Treaty applications and publication data.
- PatentScope. (2023). Chinese patent landscape reports.
- European Patent Office. (2022). Analysis of Chinese pharmaceutical patent trends.
- Liu, J., et al. (2022). "Patent landscapes for Chinese pharmaceutical innovations," Journal of IP Law.
